Department of Pharmacology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Kasumi 1-2-3, Minami-ku, Hiroshima, Japan.
Department of Pharmacology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Kasumi 1-2-3, Minami-ku, Hiroshima, Japan; Institute of Pharmacology, Tawishan Medical University, 619 Changcheng Road, Taian, Shandong 271016, China.
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:347-362. doi: 10.1016/j.pnpbp.2019.02.005. Epub 2019 Feb 11.
Clinical evidence indicates that major depression is a common comorbidity of chronic pain, including neuropathic pain. However, the cellular basis for chronic pain-mediated major depression remains unclear. High-mobility group box 1 protein (HMGB1) has a key role in innate immune responses and appears to be have a role in mediating diverse disorders, including neuropathic pain and depression. The current study aimed to characterize neuropathic pain-induced changes in affect over time and to determine whether HMGB1 has a role in neuropathic pain-induced changes in affect. Neuropathic pain was induced by partial sciatic nerve ligation (PSNL) in mice. Anxiodepressive-like behaviors in mice were evaluated over 10 weeks, in the social interaction, forced swim, and novelty suppressed feeding tests. Mice developed anxiodepressive-like behavior 6 to 8 weeks after induction of neuropathy. Accompanying anxiodepressive-like behavior, increased HMGB1 protein and microglia activation were observed in frontal cortex at 8 weeks after PSNL. Intracerebroventricular administration of rHMGB1 in naïve mice induced anxiodepressive-like behavior and microglia activation. Blockage of HMGB1 in PSNL mice with glycyrrhizic acid (GZA) or anti-HMGB1 antibody reduced microglia activation and anxiodepressive-like behavior. These results indicate that PSNL-induced anxiodepressive-like behavior is likely mediated by HMGB1. Furthermore, the data indicate that inhibition of HMGB1-dependent microglia activation could be a strategy for the treatment of depression associated with neuropathic pain.
临床证据表明,重度抑郁症是慢性疼痛(包括神经性疼痛)的常见合并症。然而,慢性疼痛导致重度抑郁症的细胞基础仍不清楚。高迁移率族蛋白 B1(HMGB1)在先天免疫反应中起关键作用,似乎在介导多种疾病中起作用,包括神经性疼痛和抑郁症。本研究旨在描述神经性疼痛随时间引起的情感变化,并确定 HMGB1 是否在神经性疼痛引起的情感变化中起作用。通过部分坐骨神经结扎(PSNL)在小鼠中诱导神经性疼痛。在社交互动、强迫游泳和新异抑制进食测试中,评估小鼠在 10 周内的焦虑抑郁样行为。在诱导神经病后 6 至 8 周,小鼠出现焦虑抑郁样行为。在 PSNL 后 8 周,额叶皮层中观察到 HMGB1 蛋白增加和小胶质细胞激活,伴随焦虑抑郁样行为。在未处理的小鼠中,脑室给予重组 HMGB1 诱导焦虑抑郁样行为和小胶质细胞激活。用甘草酸(GZA)或抗 HMGB1 抗体阻断 PSNL 小鼠中的 HMGB1 减少小胶质细胞激活和焦虑抑郁样行为。这些结果表明,PSNL 诱导的焦虑抑郁样行为可能由 HMGB1 介导。此外,数据表明抑制 HMGB1 依赖性小胶质细胞激活可能是治疗与神经性疼痛相关的抑郁症的一种策略。